Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on January 24.Invest with ...

Auvelity is an oral tablet that’s prescribed for depression. It’s a brand-name drug, and it’s not available as a generic medication. The cost of Auvelity can vary, but savings are available.

The Axsome drug, Auvelity, is already approved as a treatment for major depressive disorder. The preliminary results announced Monday are from two tests of the pill as a treatment for Alzheimer ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones ...

Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93 ...

Axsome’s commercial portfolio includes Auvelity (AXS-05) which was launched in the United States in 2022 to treat major depressive disorder. It was the company’s first approved drug.